摘要
数十年来湿性年龄相关性黄斑变性(age-related macular degeneration, AMD)已取得良好的研究进展,目前拥有多样的治疗手段,在临床上早期诊断发现湿性AMD仍至关重要,是防盲治盲工作的关键一步。当下抗血管内皮生长因子(vascular endothelial growth factor, VEGF)是临床的黄金治疗,但抗VEGF治疗周期长、费用高、复发率高、部分患者无应答。更多的有效治疗手段仍在被探讨中,包括口服抗氧化剂、中医治疗、AI技术与基因治疗,尚需进一步攻克难题。随着不断深入研究,一定能为湿性AMD患者提供更好的治疗方案。
Wet age-related macular degeneration(AMD)has been well studied for decades,and a variety of treat⁃ments are available.Early detection of wet AMD is still very important and is a key step in the prevention and treat⁃ment of blindness.Currently,anti-vascular endothelial growth factor(VEGF)is the gold clinical treatment,but anti-VEGF therapy has a long treatment cycle,high cost,high recurrence rate,and some patients have no treatment.More effective treatments are being explored,including oral antioxidants,traditional Chinese medicine,AI technology and gene therapy.There is still some work to be done.With further research,it is certain to provide better treatment op⁃tions for patients with wet AMD.
作者
朱胜钰
刘昳
ZHU Shengyu;LIU Yi(Nanjing University of Chinese Medicine,Nanjing,Jiangsu Province,210029 China;Department of Ophthalmology,Nanjing Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing,Jiangsu Province,210022 China)
出处
《系统医学》
2023年第13期186-190,共5页
Systems Medicine
关键词
湿性年龄相关性黄斑变性
研究进展
中西医治疗
AI与基因治疗
Wet age-related macular degeneration
Research progress
Chinese and western medicine treatment
AI and gene therapy
